Volume 6, Supplement 8SupplementA Critical Review of Maximal Androgen Blockade for Advanced Prostate CancerGerald W ChodakProstate cancerMaximal androgen blockadeAntiandrogensCombined androgen blockadeCastration
Volume 7, Supplement 5Review ArticlesMaximum Androgen Blockade: A Clinical UpdateGerald W ChodakMetastatic prostate cancerProstate-specific antigenLuteinizing hormone releasing hormoneMaximal androgen blockade
Volume 8, Supplement 2Review ArticlesProstate Cancer: Epidemiology, Screening, and Biomarkers16th International Prostate Cancer UpdateGerald W ChodakCarcinoma of the prostate continues to be a major health problem in the United States. Beginning in 1988, a marked increase in detection of prostate cancer occurred due to the development of a test for prostate-specific antigen (PSA). Controversy exists, however, about the value of PSA as a tumor marker. Although it has prognostic significance both before and after definitive therapy for prostate cancer, it is unclear whether routine PSA screening will translate into a survival advantage for patients. Because of its limitations, PSA may not ultimately be a good enough marker to be used as a screening tool. However, molecular biology has led to a rapid rise in the number of potential new prostate tumor markers, which may eventually overcome the weaknesses of PSA. Considerable progress has occurred in the diagnosis and management of prostate cancer: more is understood about the risk factors for the disease, possible ways to prevent it, and new ways to diagnose and monitor it. These developments have already translated into better patient care, while also identifying where further improvements are needed. [Rev Urol. 2006;8(suppl 2):S3-S8]Prostate cancerProstate-specific antigenBiomarkersProstate-specific membrane antigenProstate-specific antigen doubling time